## Nelson Chao

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/825702/publications.pdf

Version: 2024-02-01

143 papers 3,715 citations

172207 29 h-index 56 g-index

244 all docs

244 docs citations

times ranked

244

5179 citing authors

#	Article	lF	Citations
1	Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. New England Journal of Medicine, 2020, 382, 822-834.	13.9	435
2	Increasing Incidence of Chronic Graft-versus-Host Disease inÂAllogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2015, 21, 266-274.	2.0	331
3	The gut microbiota is associated with immune cell dynamics in humans. Nature, 2020, 588, 303-307.	13.7	273
4	Multi-omics analyses of radiation survivors identify radioprotective microbes and metabolites. Science, 2020, 370, .	6.0	260
5	Transfer of allogeneic CD62L– memory T cells without graft-versus-host disease. Blood, 2004, 103, 1534-1541.	0.6	247
6	Lactose drives <i>Enterococcus</i> expansion to promote graft-versus-host disease. Science, 2019, 366, 1143-1149.	6.0	217
7	The whole-genome landscape of Burkitt lymphoma subtypes. Blood, 2019, 134, 1598-1607.	0.6	113
8	Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. Blood, 2015, 125, 4085-4094.	0.6	101
9	The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD. Blood, 2020, 136, 130-136.	0.6	97
10	Increased BCR responsiveness in B cells from patients with chronic GVHD. Blood, 2014, 123, 2108-2115.	0.6	86
11	CaMKK2 in myeloid cells is a key regulator of the immune-suppressive microenvironment in breast cancer. Nature Communications, 2019, 10, 2450.	5.8	72
12	Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation, 2001, 7, 343-351.	2.0	64
13	Universal Mask Usage for Reduction of Respiratory Viral Infections After Stem Cell Transplant: A Prospective Trial. Clinical Infectious Diseases, 2016, 63, 999-1006.	2.9	63
14	Prophylaxis and Treatment of Acute Graft-Versus-Host Disease. Seminars in Hematology, 2006, 43, 32-41.	1.8	58
15	Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen. Blood, 2001, 98, 3486-3488.	0.6	53
16	Endothelial cell function and endothelialâ€related disorders following haematopoietic cell transplantation. British Journal of Haematology, 2020, 190, 508-519.	1.2	53
17	Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens. Biology of Blood and Marrow Transplantation, 2004, 10, 569-575.	2.0	51
18	Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. Biology of Blood and Marrow Transplantation, 2020, 26, 2181-2189.	2.0	51

#	Article	IF	Citations
19	A Translatable Predictor of Human Radiation Exposure. PLoS ONE, 2014, 9, e107897.	1.1	51
20	Nonmyeloablative regimen preserves "niches" allowing for peripheral expansion of donor T-cells. Biology of Blood and Marrow Transplantation, 2002, 8, 249-256.	2.0	46
21	Differential Requirements of TCR Signaling in Homeostatic Maintenance and Function of Dendritic Epidermal T Cells. Journal of Immunology, 2015, 195, 4282-4291.	0.4	46
22	Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study. Blood, 2021, 137, 1527-1537.	0.6	42
23	Graft-versus-host disease: the viewpoint from the donor T cell. Biology of Blood and Marrow Transplantation, 1997, 3, 1-10.	2.0	40
24	SYK inhibitor entospletinib prevents ocular and skin GVHD in mice. JCI Insight, 2018, 3, .	2.3	39
25	Allotransplantation for Patients Age ≥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. Biology of Blood and Marrow Transplantation, 2014, 20, 960-968.	2.0	37
26	An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD. Blood, 2017, 130, 2131-2145.	0.6	37
27	Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma. Journal of Hematology and Oncology, 2018, 11, 29.	6.9	36
28	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Advances, 2022, 6, 339-357.	2.5	35
29	HLA-Mismatched Microtransplant in Older Patients Newly Diagnosed With Acute Myeloid Leukemia. JAMA Oncology, 2018, 4, 54.	3.4	33
30	An mHealth Pain Coping Skills Training Intervention for Hematopoietic Stem Cell Transplantation Patients: Development and Pilot Randomized Controlled Trial. JMIR MHealth and UHealth, 2018, 6, e66.	1.8	31
31	Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. Biology of Blood and Marrow Transplantation, 2017, 23, 853-856.	2.0	28
32	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. Haematologica, 2020, 105, 1329-1338.	1.7	23
33	BAFF promotes heightened BCR responsiveness and manifestations of chronic GVHD after allogeneic stem cell transplantation. Blood, 2021, 137, 2544-2557.	0.6	23
34	Memory T cells: A helpful guard for allogeneic hematopoietic stem cell transplantation without causing graft-versus-host disease. Hematology/ Oncology and Stem Cell Therapy, 2017, 10, 211-219.	0.6	22
35	Calcium/calmodulin-dependent kinase kinase 2 regulates hematopoietic stem and progenitor cell regeneration. Cell Death and Disease, 2017, 8, e3076-e3076.	2.7	22
36	Survival outcomes of allogeneic hematopoietic cell transplants with EBVâ€positive or EBVâ€negative postâ€transplant lymphoproliferative disorder, A CIBMTR study. Transplant Infectious Disease, 2019, 21, e13145.	0.7	22

#	Article	IF	Citations
37	Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery. Journal of Hematology and Oncology, 2016, 9, 71.	6.9	20
38	Late effects of total body irradiation on hematopoietic recovery and immune function in rhesus macaques. PLoS ONE, 2019, 14, e0210663.	1.1	20
39	Hematopoietic Stem Cell Transplantation for CD40 Ligand Deficiency: Single Institution Experience. Pediatric Blood and Cancer, 2015, 62, 2216-2222.	0.8	19
40	MAIT and $\hat{V}$ 12 unconventional T cells are supported by a diverse intestinal microbiome and correlate with favorable patient outcome after allogeneic HCT. Science Translational Medicine, 2022, 14, .	5.8	19
41	Assessing the Feasibility of a Novel mHealth App in Hematopoietic Stem Cell Transplant Patients. Transplantation and Cellular Therapy, 2021, 27, 181.e1-181.e9.	0.6	18
42	Are We Ready for a Radiological Terrorist Attack Yet? Report From the Centers for Medical Countermeasures Against Radiation Network. International Journal of Radiation Oncology Biology Physics, 2015, 92, 504-505.	0.4	17
43	Thioredoxin mitigates radiation-induced hematopoietic stem cell injury in mice. Stem Cell Research and Therapy, 2017, 8, 263.	2.4	16
44	Pediatric Cancer in Northern Tanzania: Evaluation of Diagnosis, Treatment, and Outcomes. Journal of Global Oncology, 2018, 4, 1-10.	0.5	16
45	Calcium/Calmodulin Dependent Protein Kinase Kinase 2 Regulates the Expansion of Tumor-Induced Myeloid-Derived Suppressor Cells. Frontiers in Immunology, 2021, 12, 754083.	2,2	16
46	Toward an organ based dose prescription method for the improved accuracy of murine dose in orthovoltage xâ€ray irradiators. Medical Physics, 2014, 41, 034101.	1.6	15
47	Reduced-Intensity Allogeneic Transplantation Using Alemtuzumab from HLA-Matched Related, Unrelated, or Haploidentical Related Donors for Patients with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2014, 20, 257-263.	2.0	15
48	Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade. Cancer Letters, 2019, 440-441, 1-10.	3.2	15
49	Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 137-143.	1.3	15
50	Donor Allospecific CD44high Central Memory T Cells Have Decreased Ability to Mediate Graft-vsHost Disease. Frontiers in Immunology, 2019, 10, 624.	2.2	14
51	Insulin-Like Growth Factor 1 Protects against Lethal Irradiation. Blood, 2008, 112, 3488-3488.	0.6	14
52	Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2015, 21, 1776-1782.	2.0	13
53	Memory T Cells. Biology of Blood and Marrow Transplantation, 2008, 14, 17-22.	2.0	12
54	Myeloablative conditioning with total body irradiation for AML: Balancing survival and pulmonary toxicity. Advances in Radiation Oncology, 2016, 1, 272-280.	0.6	10

#	Article	IF	Citations
55	<p>Biodistribution and sensitive tracking of immune cells with plasmonic gold nanostars</p> . International Journal of Nanomedicine, 2019, Volume 14, 3403-3411.	3.3	10
56	Quantifying Skin Stiffness in Graft-Versus-Host Disease, Morphea, and Systemic Sclerosis Using Acoustic Radiation Force Impulse Imaging and Shear Wave Elastography. Journal of Investigative Dermatology, 2021, 141, 924-927.e2.	0.3	10
57	Prevention of Graft-Versus-Host Disease in Mouse Model Using Anti-Mouse C5 Antibody Blood, 2007, 110, 3245-3245.	0.6	10
58	Risk Factors for CMV Viremia and Treatment-Associated Adverse Events Among Pediatric Hematopoietic Stem Cell Transplant Recipients. Open Forum Infectious Diseases, 2022, 9, ofab639.	0.4	10
59	Loss of Microbiota Diversity after Autologous Stem Cell Transplant Is Comparable to Injury in Allogeneic Stem Cell Transplant. Blood, 2018, 132, 608-608.	0.6	9
60	Impact of High Dose Cyclophosphamide on the Outcome of Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma,. Blood, 2011, 118, 4127-4127.	0.6	9
61	The importance of endothelial protection: the emerging role of defibrotide in reversing endothelial injury and its sequelae. Bone Marrow Transplantation, 2021, 56, 2889-2896.	1.3	8
62	Microtransplantation in older patients with <scp>AML</scp> : A pilot study of safety, efficacy and immunologic effects. American Journal of Hematology, 2020, 95, 662-671.	2.0	7
63	Chlorhexidine Gluconate Bathing Reduces the Incidence of Bloodstream Infections in Adults Undergoing Inpatient Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 262.e1-262.e11.	0.6	7
64	Interrater Reliability of Clinical Grading Measures for Cutaneous Chronic Graft-vs-Host Disease. JAMA Dermatology, 2019, 155, 833.	2.0	6
65	Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program. Transplantation and Cellular Therapy, 2021, 27, 267.e1-267.e5.	0.6	6
66	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 2108-2117.	1.3	6
67	Chemo-Mobilization Provides Superior Mobilization and Collection in Autologous Stem Cell Transplants but with Less Predictability and At a Higher Cost,. Blood, 2011, 118, 4048-4048.	0.6	6
68	Targeting Glycolysis in Alloreactive T Cells to Prevent Acute Graft-Versus-Host Disease While Preserving Graft-Versus-Leukemia Effect. Frontiers in Immunology, 2022, 13, 751296.	2.2	6
69	Efficacy and safety of highâ€dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma. Hematological Oncology, 2017, 35, 752-759.	0.8	5
70	House calls for stem cell transplant patients during the COVID-19 pandemic. Blood, 2020, 136, 370-371.	0.6	5
71	Differential Impact of Inhibitory and Activating Killer Ig-Like Receptors and HLA Ligand on Outcomes of Transplantation for Myeloid and Lymphoid Malignancies Blood, 2008, 112, 3255-3255.	0.6	5
72	Partially HLA Matched, Non-Myeloablative Allogeneic Transplantation Blood, 2005, 106, 2896-2896.	0.6	5

#	Article	IF	CITATIONS
73	Highâ€dose intravenous immunoglobulin as adjuvant treatment for grade <scp>IV</scp> acute cutaneous graftâ€versusâ€host disease. British Journal of Dermatology, 2019, 181, 869-871.	1.4	4
74	Pre-transplant hepatic steatosis (fatty liver) is associated with chronic graft-vs-host disease but not mortality. PLoS ONE, 2020, 15, e0238824.	1.1	4
75	Decreased Mortality in 1-Year Survivors of Umbilical Cord Blood Transplant vs. Matched Related or Matched Unrelated Donor Transplant in Patients with Hematologic Malignancies. Transplantation and Cellular Therapy, 2021, 27, 669.e1-669.e8.	0.6	4
76	Female Sex Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 784.e1-784.e7.	0.6	4
77	Intestinal Enterococcus Is a Major Risk Factor for the Development of Acute Gvhd. Blood, 2018, 132, 358-358.	0.6	4
78	A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant. PLoS ONE, 2021, 16, e0252995.	1.1	3
79	Surgical Mask Usage Reduces the Incidence of Parainfluenza Virus 3 in Recipients of Stem Cell Transplantation. Blood, 2012, 120, 462-462.	0.6	3
80	Fibrinogen-Coated Albumin Nanospheres Prevent Thrombocytopenia-Related Bleeding. Radiation Research, 2020, 194, 162.	0.7	3
81	Home-Based Hematopoietic Cell Transplantation in the United States. Transplantation and Cellular Therapy, 2022, 28, 207.e1-207.e8.	0.6	3
82	What Do You Do with the "Pink Sheets?― Hematology American Society of Hematology Education Program, 2008, 2008, 23-25.	0.9	2
83	Study Limitations in HLA-Mismatched Microtransplant in Older Patients Newly Diagnosed With Acute Myeloid Leukemiaâ€"Reply. JAMA Oncology, 2018, 4, 891.	3.4	2
84	Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant. Blood Cancer Journal, 2021, 11, 92.	2.8	2
85	Plerixafor (Mozobil®) Selectively Enhances Donor Hematopoietic Cell Engraftment Blood, 2009, 114, 368-368.	0.6	2
86	Cognitive impairment in candidates for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, $2021, \ldots$	1.3	2
87	Human Memory T Cells Proliferate but Do Not Elicit Cytotoxicity in Response to Alloantigens Blood, 2004, 104, 1229-1229.	0.6	2
88	Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. Bone Marrow Transplantation, 2018, 53, 932-937.	1.3	1
89	Campath-1H May Have Activity in the Treatment of Multiple Myeloma Blood, 2004, 104, 4931-4931.	0.6	1
90	A Prospective Study of Bortezomib in Combination with Melphalan and Prednisone for Patients with Previously Untreated Multiple Myeloma Blood, 2005, 106, 5181-5181.	0.6	1

#	Article	IF	CITATIONS
91	Adult Umbilical Cord Blood Transplantation Following Non-Myeloablative Conditioning; Impact of Increased Cell Dose and 200cGy TBI on Engraftment and Survival Blood, 2006, 108, 5399-5399.	0.6	1
92	Safety Trial of NK Cell Enhanced Donor Lymphocyte Infusions from a 3-5/6 HLA Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation. Blood, 2008, 112, 342-342.	0.6	1
93	Pleiotrophin Signaling Is Necessary and Sufficient for Hematopoietic Stem Cell Self-Renewal In Vivo. Blood, 2010, 116, 404-404.	0.6	1
94	Allogeneic Effector Memory T Cells Enhance Hematopoietic Engraftment and Immune Reconstitution After Stem Cell Transplantation. Blood, 2010, 116, 78-78.	0.6	1
95	High Dose BCNU/Melphalan Preparative Regimen Doubles Event Free Survival of Myeloma Patients Undergoing Autologous Transplantation. Blood, 2011, 118, 2012-2012.	0.6	1
96	Inferior survival after microbiota injury: A multicenter allo-HCT study Journal of Clinical Oncology, 2019, 37, 7015-7015.	0.8	1
97	Myeloablative Intravenous Busulfan/Fludarabine Conditioning Does Not Facilitate Reliable Engraftment of Dual Umbilical Cord Blood Grafts in Adult Recipients Blood, 2007, 110, 2007-2007.	0.6	1
98	Pleiotrophin Is a Growth Factor for Hematopoietic Stem Cells and Induces Stem Cell Self-Renewal. Blood, 2008, 112, 78-78.	0.6	1
99	Allogeneic Stem Cell Transplantation with Omidubicel: Long-Term Follow-up from a Single Center. Blood, 2021, 138, 1827-1827.	0.6	1
100	You Cannot Improve What You Do Not Measure. Biology of Blood and Marrow Transplantation, 2012, 18, 1467-1468.	2.0	0
101	Verification of a novel method for tube voltage constancy measurement of orthovoltage xâ€ray irradiators. Medical Physics, 2014, 41, 084101.	1.6	0
102	Novel Cellular Therapeutic Approaches for the Prevention and Management of Graft-Versus-Host Disease. Current Stem Cell Reports, 2018, 4, 318-326.	0.7	0
103	Transplantation without pretransplant therapy: Is this a possibility? Insights into providing transplantation at diagnosis for patients with acute leukemia. Best Practice and Research in Clinical Haematology, 2019, 32, 101108.	0.7	0
104	I have a gut feeling…. Blood, 2020, 136, 1380-1380.	0.6	0
105	Clinical and Neuroimaging Correlates of Post-Transplant Delirium. Biology of Blood and Marrow Transplantation, 2020, 26, 2323-2328.	2.0	0
106	Promotion of Stem Cell-Derived New T Cell Generation by CD62Lâ^' Memory T Cells Requires Alloantigen Recognition Blood, 2004, 104, 3041-3041.	0.6	0
107	Multimodal Dose Dense Therapy for Mantle Cell Lymphoma Blood, 2005, 106, 5501-5501.	0.6	0
108	Blocking Complement-Mediated Hemolysis Using RNA Aptamers That Bind Complement Component C8 Blood, 2005, 106, 186-186.	0.6	0

#	Article	IF	CITATIONS
109	Concomitant Induction of CMVpp65-Specific CD4+ and CD8+ T Cells Using Dendritic Cells Transfected with mRNA Encoding an Invariant Chain-pp65 Fusion Protein Blood, 2005, 106, 3243-3243.	0.6	O
110	Phase I Study of Gemcitabine, Fludarabine and Mitoxantrone for Relapsed or Refractory Leukemia Blood, 2005, 106, 4623-4623.	0.6	0
111	Prevention of Graft-Versus-Host Disease by Selective Depletion of Alloreactive T Cells Blood, 2006, 108, 3174-3174.	0.6	0
112	In Vivo Radiaprotective Effects of Growth Hormone Blood, 2006, 108, 5158-5158.	0.6	0
113	A Pilot Trial of Two Dose Levels of Rabbit Antithymocyte Globulin, (rATG), Thymoglobulin, as Part of a Myeloablative-Conditioning for a HLA Identical Matched Related Donor Stem Cell Transplant (SCT) with Cyclosporine (CsA) as Graft Versus Host Disease (GvHD) Prophylaxis Blood, 2006, 108, 5369-5369.	0.6	0
114	The Retinoid X Receptor Regulates Human Hematopoietic Stem Cell Fate Blood, 2006, 108, 1324-1324.	0.6	0
115	Allogeneic Committed Hematopoietic Progenitors Are Protective Against Radiation Blood, 2007, 110, 4871-4871.	0.6	0
116	Endothelial Progenitor Cell Transplantation for Hematopoietic Regeneration Blood, 2007, 110, 179-179.	0.6	0
117	Treatment of Established Graft-Versus-Host Disease by PG490-88 Blood, 2007, 110, 3243-3243.	0.6	0
118	Identification of Pleiotrophin as a Novel Growth Factor for Hematopoietic Stem and Progenitor Cells Blood, 2007, 110, 1404-1404.	0.6	0
119	Total Body Irradiation 1350cGy/Fludarabine (TBI/FLU) vs Myeloablative Busulfan/Fludarabine (Bu/Flu) Preparation in Adult Recipients of Dual Umbilical Cord Blood (UCB) Transplantation: Superior Engraftment with Low Treatment-Related Mortality. Blood, 2008, 112, 4403-4403.	0.6	0
120	Bortezomib Plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Non-Transplant Candidates in Patients with Previously Untreated Multiple Myeloma Blood, 2008, 112, 3325-3325.	0.6	0
121	Early Pre/Post Fluoro-Deoxyglucose Positive Emission Tomography (PET) Does Not Predict Outcome of Patients Undergoing Hematopoietic Stem Cell Transplantation in Hodgkins Disease and Non-Hodgkins Lymphoma Blood, 2008, 112, 2180-2180.	0.6	0
122	A Prospective Study of Donor ImmuKnow $\hat{A}^{\otimes}$ as a Biomarker for Acute GvHD in Hematopoietic Cell Transplantation Recipients Blood, 2009, 114, 4646-4646.	0.6	0
123	Allospecific Effector Memory T Cells Are Able to Mediate Second-Set Skin Graft Rejection but Unable to Induce Graft-Versus-Host Disease Blood, 2009, 114, 232-232.	0.6	0
124	Deletion of Bak and Bax in Tie2+ BM Hematopoietic Stem Cells Induces a B Cell Lymphoproliferative Disorder Blood, 2009, 114, 1247-1247.	0.6	0
125	Hematopoietic Stem Cell Transplantation Across Genetic Barriers Using a Nonmyeloablative Conditioning Regimen., 2010, , 119-162.		0
126	VE Cadherin Positive Endothelial Cells Regulate Hematopoietic Reconstitution In Vivo Blood, 2010, 116, 3734-3734.	0.6	0

#	Article	IF	CITATIONS
127	Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350cGy) and Fludarabine Conditioning. Blood, 2010, 116, 3523-3523.	0.6	O
128	Risk-Factors for Acute Graft-Versus-Host Disease and Survival After Hematopoietic Cell Transplantation From Siblings and Unrelated Donors – An Analysis of the CIBMTR. Blood, 2010, 116, 897-897.	0.6	0
129	Facilitation of Hematopoietic Reconstitution Via Inhibition of Bone Marrow Endothelial Cell-Mediated SDF-1 Signaling Blood, 2010, 116, 3859-3859.	0.6	0
130	Prospective, Biological Randomized Study of T-Cell Depleted Nonmyeloablative Allogeneic Transplantation From HLA-Matched Related, Unrelated or Haploidentical Donors for Patients with Hematologic Malignancies. Blood, 2010, 116, 3541-3541.	0.6	0
131	An Ear-Tissue Model for High-Resolution In Vivo Imaging Blood, 2010, 116, 1456-1456.	0.6	0
132	A Comprehensive Comparison Immune Recovery In Adult Patients Following Allogeneic Umbilical Cord Blood, Matched Sibling and Matched Unrelated Donor Stem Cell Transplantation. Blood, 2010, 116, 2313-2313.	0.6	0
133	The Impact of Lymphocyte Subset Recovery At 3 Months on Progression-Free Survival After Myeloablative Allogeneic Stem Cell Transplantation,. Blood, 2011, 118, 4065-4065.	0.6	0
134	Differences in Stem Cell Collection Practices and Related Outcomes Between Centers That Conduct and Do Not Conduct Aphaeresis on Weekends. Blood, 2011, 118, 1925-1925.	0.6	0
135	A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients with Relapsed/Refractory Mulitple Myeloma. Blood, 2011, 118, 5129-5129.	0.6	0
136	Blazing a new TRAIL in hematopoietic cell transplantation. Journal of Clinical Investigation, 2013, 123, 2362-2363.	3.9	0
137	Calcium/Calmodulin Dependent Protein Kinase Kinase 2 (CaMKK2) Expressed in the Host Promotes Lymphoma Cells Growth By Controlling Myeloid Derived Suppressor Cells Expansion. Blood, 2018, 132, 272-272.	0.6	0
138	Endothelial Cell-Derived Extracellular Vesicles Mitigate Radiation-Induced Hematopoietic Injury. Blood, 2018, 132, 2581-2581.	0.6	0
139	Pre-Transplant Hepatic Steatosis (fatty liver) Predicts Chronic Graft-Vs-Host Disease but Does Not Affect Mortality. Blood, 2019, 134, 5731-5731.	0.6	0
140	Female Gender Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplant. Blood, 2020, 136, 18-19.	0.6	0
141	Morphologic Leukemia-Free State in Acute Myeloid Leukemia Is Sufficient for Successful Allogeneic Hematopoietic Stem Cell Transplant. Blood, 2020, 136, 24-25.	0.6	0
142	Financial incentives to increase stool collection rates for microbiome studies in adult bone marrow transplant patients. PLoS ONE, 2022, 17, e0267974.	1.1	0
143	GVHD…it is all about the microenvironment!. Blood, 2022, 139, 2853-2854.	0.6	0